Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

@article{Gold2012PlacebocontrolledP3,
  title={Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.},
  author={R. Gold and L. Kappos and D. Arnold and A. Bar-Or and G. Giovannoni and K. Selmaj and Carlo Tornatore and M. Sweetser and M. Yang and S. Sheikh and K. T. Dawson},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 12},
  pages={
          1098-107
        }
}
  • R. Gold, L. Kappos, +8 authors K. T. Dawson
  • Published 2012
  • Medicine
  • The New England journal of medicine
  • BACKGROUND BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis. METHODS We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis. Patients were randomly… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This will be a 1:1 randomized open label trial. European and outside Europe centres will be involved. Aim of the project is to conduct a head-to-head comparison of effectiveness of two… Expand
    ConditionsRelapsing Remitting Multiple Sclerosis
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to explore whether DMF (Dimethyl Fumarate) or MMF (monomethyl fumarate) its main bioactive metabolite, is capable of entering the central nervous system in… Expand
    ConditionsMultiple Sclerosis
    InterventionDrug

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 22 REFERENCES
    A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
    2558